Lazertinib 160mg in EGFR T790M NSCLC

Clinical trial NCT05701384 · UNKNOWN

Trial details

NCT number: NCT05701384
Sponsor: Samsung Medical Center
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Cancer Stage IV EGFR T790M

Start date: 2023-02-01
Primary completion: 2024-01-31
Enrollment: 117

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.